Welcome to our dedicated page for Masimo SEC filings (Ticker: MASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Masimo Corporation (MASI) SEC filings page on Stock Titan provides access to the company e2 80 99s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Masimo, a Delaware corporation and global medical technology company, reports under Commission File Number 001-33642. Its filings offer detailed insight into financial performance, corporate actions, and material events related to its healthcare-focused monitoring technologies and related operations.
Recent Form 8-K filings document key developments, such as quarterly financial results, guidance updates, and significant transactions. For example, Masimo filed a Form 8-K on November 4, 2025, furnishing a press release that reported third quarter 2025 financial results for its continuing healthcare operations and provided updated full-year 2025 guidance. Earlier, on August 5, 2025, the company filed a Form 8-K to furnish second quarter 2025 results and supplemental financial information.
Masimo e2 80 99s filings also record corporate events beyond earnings. A Form 8-K dated September 23, 2025 describes the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, including the transfer of Masimo e2 80 99s equity interests in Viper Holdings Corporation and related cash consideration. Another Form 8-K filed on August 19, 2025 notes the resignation of a board member, while additional 8-Ks provide unaudited pro forma financial information following the Sound United transaction.
Within these filings, Masimo explains its use of non-GAAP financial measures, outlining adjustments for items such as acquisition-related amortization, business transition and related costs, litigation-related expenses and settlements, realized and unrealized gains or losses, financing-related adjustments, and tax impacts. Investors reviewing this page can use the underlying documents alongside Stock Titan e2 80 99s AI-powered summaries to understand Masimo e2 80 99s reported GAAP and non-GAAP results, the impact of significant transactions, and disclosures about ongoing Apple-related litigation expenses. The filings archive is a primary source for Masimo e2 80 99s official, time-stamped communications with regulators and the market.
Masimo Corporation and Danaher Corporation disclosed communications and preliminary solicitation materials related to a proposed transaction in which Danaher agreed to acquire Masimo. Masimo and Danaher state they will file Masimo’s proxy statement and mail a definitive proxy card to Masimo stockholders in connection with the stockholder meeting.
The companies caution that the Transaction’s timing and completion are subject to customary conditions, including Masimo stockholder approval and required regulatory clearances, and list typical transactional risks and limits on pre-close engagement.
Masimo Corp executive Micah W. Young reported equity award activity involving company common stock. He acquired 2,034 shares at no cost in connection with the vesting of previously granted performance-based restricted stock units that vested upon achievement of three-year performance goals. To cover related tax withholding obligations, 1,123 shares were disposed of by being withheld by Masimo at a price of $175.22 per share, leaving him with 18,347 shares held directly after these transactions.
Masimo Corporation’s annual report outlines a major strategic shift centered on its core medical-technology platform and a pending sale of the company. Masimo develops noninvasive monitoring, hospital automation and connectivity products built on its Masimo SET and rainbow platforms, sold to hospitals and OEM partners worldwide.
The company completed the sale of its non‑healthcare consumer audio business, Sound United, to Harman International, a Samsung subsidiary, on September 23, 2025, sharpening its focus on healthcare. Masimo has also agreed to be acquired by Danaher: each outstanding share will be converted into the right to receive $180.00 in cash, without interest, if the merger closes.
The merger, expected in the second half of 2026, remains subject to stockholder approval and multiple regulatory clearances, and the risk section highlights that delays, failure to obtain approvals, and deal uncertainty could adversely affect operations. The filing also details extensive regulatory, reimbursement, privacy, and anti‑kickback frameworks governing Masimo’s business, plus key risks tied to intellectual property, OEM and GPO relationships, and government oversight.
Masimo Corporation’s major shareholder Politan Capital has updated its ownership filing after a merger announcement with Danaher. Politan and related entities report beneficial ownership of 4,590,873 Masimo common shares, representing 6.2% of the company, based on 74,218,782 shares outstanding as of February 13, 2026.
Masimo agreed to a merger in which a Danaher subsidiary will combine with Masimo, leaving Masimo as a wholly owned Danaher subsidiary. In connection with this, Politan entered into a Voting and Support Agreement committing to vote its Masimo shares in favor of adopting the merger agreement and approving the merger, and agreeing to customary transfer restrictions.
The filing notes that no Masimo share transactions were made by the reporting persons in the past 60 days and that a portion of their holdings is pledged under a standard margin loan facility.
Danaher Corporation plans to acquire Masimo Corporation in an all-cash deal valuing Masimo at $180 per share, or about $9.9 billion in enterprise value including assumed debt and net of cash. Masimo is a leading provider of pulse oximetry and other patient monitoring technologies, mainly for acute care.
Masimo will operate as a standalone business within Danaher’s Diagnostics segment alongside brands such as Radiometer and Beckman Coulter Diagnostics. Danaher expects Masimo to deliver high-single digit core revenue growth over the long term and to generate more than $530 million of EBITDA in 2027.
The acquisition is projected to increase Danaher’s adjusted diluted net earnings per share by $0.15–$0.20 in the first full year and about $0.70 in the fifth full year. Danaher also targets over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year. Closing is anticipated in the second half of 2026, subject to regulatory clearances and Masimo shareholder approval, and will be funded with cash on hand and new debt.
Masimo Corporation agreed to be acquired by Danaher Corporation in an all-cash merger valuing Masimo at $180.00 per share, or about $9.9 billion. Masimo will become a standalone business unit within Danaher’s Diagnostics segment and continue operating under the Masimo brand.
The deal requires approval from Masimo stockholders, antitrust and foreign investment clearances, and other customary closing conditions. A voting agreement with Politan Capital Management supports the merger, and Masimo could owe Danaher a $305 million termination fee in certain scenarios. Closing is expected in the second half of 2026, after which Masimo’s shares will be delisted and deregistered.
Masimo Corporation: Joe Kiani reports beneficial ownership of 5,904,629 shares of common stock, representing 10.3% of the class as calculated in the filing. The reported total combines issued shares and multiple equity awards that the filer says remain issuable but which the company has not issued.
The filing details that 368,252 shares relate to exercised options the company declined to process and that the filer includes 2,700,000 RSUs, 158,450 accelerated options, 198,225 PSUs, and 85,255 vested options among the components of the aggregate beneficial ownership; several of those items are subject to a dispute described in footnotes.
Masimo Corporation CEO Catherine M. Szyman reported equity compensation activity on February 12, 2026. She exercised 11,141 restricted stock units (RSUs), converting them into 11,141 shares of common stock at a price of $132.96 per share. Of these, 4,568 shares were withheld by Masimo to cover tax withholding obligations tied to the vesting of performance RSUs, leaving her with 6,573 shares of common stock held directly. Following the transaction, she also directly held 22,283 RSUs, which continue to represent the right to receive an equal number of common shares upon future vesting.
Masimo Corporation executive Sampath Anand, EVP of Ops & Clinical Research, exercised stock options and sold shares of common stock. On January 28, 2026, he exercised 30,000 non-qualified stock options at an exercise price of
That same day he sold Masimo common stock in three transactions under a Rule 10b5-1 sales plan dated September 12, 2025. He sold 11,924 shares at a weighted average price of
Masimo Corporation has received a notice under Rule 144 for the proposed sale of 18,680 shares of its common stock through broker Charles Schwab & Co., Inc. on NASDAQ. The aggregate market value of the shares listed for sale is $2,555,567.00.
The seller acquired the 18,680 shares on 01/28/2026 through an employee stock option exercise, with a broker-facilitated cashless exercise used as payment. The filing notes that 53,713,949 common shares are outstanding and includes standard representations about the absence of undisclosed material adverse information.